These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid. Rafa H; Saoula H; Belkhelfa M; Medjeber O; Soufli I; Toumi R; de Launoit Y; Moralès O; Nakmouche M; Delhem N; Touil-Boukoffa C J Interferon Cytokine Res; 2013 Jul; 33(7):355-68. PubMed ID: 23472658 [TBL] [Abstract][Full Text] [Related]
5. Innate and adaptive immunity in inflammatory bowel disease. Geremia A; Biancheri P; Allan P; Corazza GR; Di Sabatino A Autoimmun Rev; 2014 Jan; 13(1):3-10. PubMed ID: 23774107 [TBL] [Abstract][Full Text] [Related]
6. IL-23/IL-17 axis in IBD. Sarra M; Pallone F; Macdonald TT; Monteleone G Inflamm Bowel Dis; 2010 Oct; 16(10):1808-13. PubMed ID: 20222127 [TBL] [Abstract][Full Text] [Related]
7. Inflammatory bowel disease: beyond the boundaries of the bowel. Actis GC; Rosina F; Mackay IR Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):401-10. PubMed ID: 21651357 [TBL] [Abstract][Full Text] [Related]
8. Total Glycosides of Peony Protects Against Inflammatory Bowel Disease by Regulating IL-23/IL-17 Axis and Th17/Treg Balance. Li Q; Shan Q; Sang X; Zhu R; Chen X; Cao G Am J Chin Med; 2019; 47(1):177-201. PubMed ID: 30612460 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-23/Th17 pathways and inflammatory bowel disease. Abraham C; Cho J Inflamm Bowel Dis; 2009 Jul; 15(7):1090-100. PubMed ID: 19253307 [TBL] [Abstract][Full Text] [Related]
10. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease. Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533 [TBL] [Abstract][Full Text] [Related]
11. The interleukin-23 axis in intestinal inflammation. Ahern PP; Izcue A; Maloy KJ; Powrie F Immunol Rev; 2008 Dec; 226():147-59. PubMed ID: 19161422 [TBL] [Abstract][Full Text] [Related]
13. miRNAs as new molecular insights into inflammatory bowel disease: Crucial regulators in autoimmunity and inflammation. Xu XM; Zhang HJ World J Gastroenterol; 2016 Feb; 22(7):2206-18. PubMed ID: 26900285 [TBL] [Abstract][Full Text] [Related]
14. Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad. Troncone E; Marafini I; Pallone F; Monteleone G Int Rev Immunol; 2013; 32(5-6):526-33. PubMed ID: 24041379 [TBL] [Abstract][Full Text] [Related]
16. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases. Bunte K; Beikler T Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295952 [TBL] [Abstract][Full Text] [Related]
17. Recent advances in IBD pathogenesis: genetics and immunobiology. Shih DQ; Targan SR; McGovern D Curr Gastroenterol Rep; 2008 Dec; 10(6):568-75. PubMed ID: 19006613 [TBL] [Abstract][Full Text] [Related]
18. Immunopathogenesis of IBD: Batf as a Key Driver of Disease Activity. Hildner K; Punkenburg E; Abendroth B; Neurath MF Dig Dis; 2016; 34 Suppl 1():40-7. PubMed ID: 27548324 [TBL] [Abstract][Full Text] [Related]
19. Th17 plasticity and its changes associated with inflammatory bowel disease. Ueno A; Ghosh A; Hung D; Li J; Jijon H World J Gastroenterol; 2015 Nov; 21(43):12283-95. PubMed ID: 26604637 [TBL] [Abstract][Full Text] [Related]
20. Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL-17A expression and inflammation in the intestinal mucosa. Kim DJ; Kim KS; Song MY; Seo SH; Kim SJ; Yang BG; Jang MH; Sung YC Clin Immunol; 2012 Sep; 144(3):190-9. PubMed ID: 22836084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]